MONMOUTH JUNCTION, N.J., Sept. 19, 2006 (PRIMEZONE) -- MedaSorb Technologies, Inc. (OTCBB:MSBT) announced today that they intend to file an Investigational Device Exemption (IDE) with the FDA by the end of the year for CytoSorb(tm)'s Drug Detoxification indication. The Company is in contact with the FDA regarding an informal guidance meeting to confirm its approach for testing and development of the indication while preparing the final documentation for the submission. MedaSorb is confident the performance of CytoSorb(tm)'s adsorbent bead technology for Drug Detoxification is superior to current charcoal filter technology for removing drugs toxins from the blood stream in overdose traumas. MedaSorb anticipates this will be the first indication to achieve 510K approval for CytoSorb(tm).
